Trial shows MRI-guided targeted biopsy may miss prostate cancer in younger men, implying need for systematic samples.
We looked at the effectiveness of systematic biopsy (usually 12 cores taken from the prostate gland) and targeted biopsy (cores from a suspicious area seen on a scan) of the prostate among men aged 45-54 years as part of a prostate cancer screening trial. The results show that using only two targeted cores per lesion seen on an MRI (magnetic resonance imaging) scan may miss a significant number of clinically relevant prostate cancers. One reason could be that MRI-targeted biopsies are not always perfectly accurate. To improve diagnostic accuracy in younger men, it may be necessary to take additional systematic tissue samples, or at least more samples from around any suspicious area. This trial is registered on ISRCTN as ISRCTN37591328.
No takes yet. Share an insight, caveat, or question.
Al-Monajjed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: